关注并星标CPHI制药在线*展会预登记火热进行中, 扫描二维码免费领票!近日,GSK发布2025Q2财报,在财报中,GSK披露其TIM3抗体cobolimab联合PD‑1抗体dostarlimab的Ⅲ期临床试验,未能达到总生存期(OS)主要终点,相比对照组,cobolimab+ dostarlimab+docetaxel(多西他赛)未能提高非小细胞肺癌(NSCLC)患者的总生存期。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.